



Contents lists available at ScienceDirect

## Bioorganic & Medicinal Chemistry Letters

journal homepage: [www.elsevier.com/locate/bmcl](http://www.elsevier.com/locate/bmcl)



### Corrigendum

Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RAR $\beta$  agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]



Maria B. Goncalves<sup>a</sup>, Earl Clarke<sup>a</sup>, Christopher I. Jarvis<sup>a</sup>, S. Barret Kalindjian<sup>a</sup>, Thomas Pitcher<sup>a</sup>, John Grist<sup>a</sup>, Carl Hobbs<sup>a</sup>, Thomas Carlstedt<sup>a</sup>, Julian Jack<sup>a</sup>, Jane T. Brown<sup>c</sup>, Mark Mills<sup>c</sup>, Peter Mumford<sup>c</sup>, Alan D. Borthwick<sup>b,\*</sup>, Jonathan P.T. Corcoran<sup>a,\*</sup>

<sup>a</sup> Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK

<sup>b</sup> DrugMolDesign, 15 Temple Grove, London NW11 7UA, UK

<sup>c</sup> Sygnature Discovery Limited, Biocity, Pennyfoot Street, Nottingham NG1 1GF, UK

The authors regret that a mistake was made in the headings of Tables 2 and 3. The correct Tables 2 and 3 appear below.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.bmcl.2019.02.011>

\* Corresponding authors.


E-mail addresses: [alan.d.borthwick@drugmol.design](mailto:alan.d.borthwick@drugmol.design) (A.D. Borthwick), [jonathan.corcoran@kcl.ac.uk](mailto:jonathan.corcoran@kcl.ac.uk) (J.P.T. Corcoran).

<https://doi.org/10.1016/j.bmcl.2019.05.058>

Available online 14 June 2019

0960-894X/ © 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).


**Table 2**  
1,2,4-Oxadiazol-3-yl benzoic acid derivatives in RAR  $\alpha$ ,  $\beta$  and  $\gamma$  transactivation assays.<sup>a</sup>



Compd	X	$\beta$ EC <sub>50</sub> nM <sup>d</sup>	$\alpha$ EC <sub>50</sub> nM <sup>d</sup>	$\gamma$ EC <sub>50</sub> nM <sup>d</sup>	Fold Selectivity for $\beta$ over $\alpha$ <sup>b</sup>	Fold Selectivity for $\beta$ over $\gamma$ <sup>b</sup>	cLog P <sup>d</sup>
ATRA	–	1.9	1.2	0.9	0.6	0.5	
5		1.5	18 <sup>c</sup>	28	12	19	5.1
8		4200	18	17	0.0043	0.0041	7.2
9		1.4	4	3	2.8	2.1	7.2
10		1.9	26	11	13	5.6	5.3
11		2.5	19	5.3	7.6	2	5.3
12		3.4	30	6.3	9	2	5.8
13		11	114	83	10	7.5	4.1

<sup>a-d</sup> See Table 1.

**Table 3**  
Derivatives of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid in the RAR  $\alpha$ ,  $\beta$  and  $\gamma$  transactivation assays.<sup>a</sup>



Compd	R	$\beta$ EC <sub>50</sub> nM <sup>d</sup>	$\alpha$ EC <sub>50</sub> nM <sup>d</sup>	$\gamma$ EC <sub>50</sub> nM <sup>d</sup>	Fold Selectivity for $\beta$ over $\alpha$ <sup>b</sup>	Fold Selectivity for $\beta$ over $\gamma$ <sup>b</sup>	cLog P <sup>d</sup>
10	H	1.9	26	11	13	5.6	5.3
14	2-F	2.2	16	8.4	7.3	3.8	5.1
15	2-Me	14	89	25	6.4	1.8	5.5
16	3-F	11	61	3.7	5.5	0.33	5.5
17	3-Me	47	600	14	13	0.3	5.5

<sup>a,b,d</sup> See Table 1.